Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
Micevic G, Theodosakis N, Bosenberg M. Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. Clinical Epigenetics 2017, 9: 34. PMID: 28396701, PMCID: PMC5381063, DOI: 10.1186/s13148-017-0332-8.Peer-Reviewed Original ResearchMeSH KeywordsAzacitidineBiomarkers, TumorDecitabineDNA MethylationEpigenesis, GeneticGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMelanomaMicroRNAsPrognosisConceptsAberrant DNA methylationDNA methylationMethylation changesDNA methylation changesEpigenetic hallmarkMelanoma formationMethylation signaturesMethylationImportant unresolved questionsBiomarker opportunitiesTherapeutic opportunitiesTherapeutic developmentMethylation methodUnresolved questionsTherapeutic potentialImportant roleRecent advancesPotential biomarkersGenesRecent developmentsHallmarkConsiderable effortDevelopmentBiomarkersAdvances